{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:19:58Z","timestamp":1777450798564,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T00:00:00Z","timestamp":1431993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T00:00:00Z","timestamp":1431993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Our previous studies have shown that mangiferin decreased serum triglycerides and free fatty acids (FFAs) by increasing FFAs oxidation in both animal and cell experiments. This study sought to evaluate the effects of mangiferin on serum lipid profiles in overweight patients with hyperlipidemia. Overweight patients with hyperlipidemia (serum triglyceride \u2265 1.70\u2009mmol\/L and total cholesterol \u2265 5.2\u2009mmol\/L) were included in this double-blind randomized controlled trial. Participants were randomly allocated to groups, either receiving mangiferin (150\u2009mg\/day) or identical placebo for 12 weeks. The lipid profile and serum levels of mangiferin, glucose, L-carnitine, \u03b2-hydroxybutyrate and acetoacetate were determined at baseline and 12 weeks. A total of 97 participants completed the trial. Compared with the placebo control, mangiferin supplementation significantly decreased the serum levels of triglycerides and FFAs and insulin resistance index. Mangiferin supplementation also significantly increased the serum levels of mangiferin, high-density lipoprotein cholesterol, L-carnitine, \u03b2-hydroxybutyrate and acetoacetate and increased lipoprotein lipase activity. However, there were no differences in the serum levels of total cholesterol, low-density lipoprotein cholesterol, serum glucose and insulin between groups. Mangiferin supplementation could improve serum lipid profiles by reducing serum triglycerides and FFAs in overweight patients with hyperlipidemia, partly due to the promotion of FFAs oxidation.<\/jats:p>","DOI":"10.1038\/srep10344","type":"journal-article","created":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T16:40:47Z","timestamp":1432053647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial"],"prefix":"10.1038","volume":"5","author":[{"given":"Lixin","family":"Na","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changhao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yucun","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,19]]},"reference":[{"key":"BFsrep10344_CR1","first-page":"149","volume":"15","author":"T Lucchi","year":"2014","unstructured":"Lucchi, T. & Vergani, C. [Dyslipidemias and statins: from guidelines to clinical practice. An updated review of the literature]. G Ital Cardiol (Rome). 15, 149\u201360 (2014).","journal-title":"G Ital Cardiol (Rome)"},{"key":"BFsrep10344_CR2","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s11427-011-4225-3","volume":"54","author":"K Yin","year":"2011","unstructured":"Yin, K. & Tang, C. Inflammation, lipid metabolism dysfunction and hypertension: active research fields in atherosclerosis-related cardiovascular disease in China. Sci China Life Sci. 54, 976\u20139 (2011).","journal-title":"Sci China Life Sci."},{"key":"BFsrep10344_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","volume":"384","author":"BG Nordestgaard","year":"2014","unstructured":"Nordestgaard, B.G. & Varbo, A. Triglycerides and cardiovascular disease. Lancet. 384, 626\u201335 (2014).","journal-title":"Lancet"},{"key":"BFsrep10344_CR4","doi-asserted-by":"publisher","first-page":"13F","DOI":"10.1016\/S0002-9149(99)00209-X","volume":"83","author":"MA Austin","year":"1999","unstructured":"Austin, M.A. Epidemiology of hypertriglyceridemia and cardiovascular disease. Am J Cardiol. 83, 13F\u201316F (1999).","journal-title":"Am J Cardiol."},{"key":"BFsrep10344_CR5","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.3390\/nu6031236","volume":"6","author":"S Matsumoto","year":"2014","unstructured":"Matsumoto, S., et al. The role of hypertriglyceridemia in the development of atherosclerosis and endothelial dysfunction. Nutrients. 6, 1236\u201350 (2014).","journal-title":"Nutrients"},{"key":"BFsrep10344_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0021-9150(01)00588-3","volume":"160","author":"M Pirro","year":"2002","unstructured":"Pirro, M., et al. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Atherosclerosis. 160, 377\u201384 (2002).","journal-title":"Atherosclerosis"},{"key":"BFsrep10344_CR7","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.2337\/db12-1122","volume":"62","author":"BI Frohnert","year":"2013","unstructured":"Frohnert, B.I., et al. Relation between serum free fatty acids and adiposity, insulin resistance and cardiovascular risk factors from adolescence to adulthood. Diabetes. 62, 3163\u20139 (2013).","journal-title":"Diabetes"},{"key":"BFsrep10344_CR8","doi-asserted-by":"publisher","first-page":"III19","DOI":"10.1002\/clc.4960261505","volume":"26","author":"HB Brewer Jr.","year":"2003","unstructured":"Brewer, H.B., Jr. New features of the National Cholesterol Education Program Adult Treatment Panel III lipid-lowering guidelines. Clin. Cardiol. 26, III19\u201324 (2003).","journal-title":"Clin. Cardiol."},{"key":"BFsrep10344_CR9","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1365-2265.2008.03490.x","volume":"70","author":"D Preiss","year":"2009","unstructured":"Preiss, D. & Sattar, N. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin. Endocrinol. (Oxf). 70, 815\u201328 (2009).","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"BFsrep10344_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2133.1996.tb16233.x","volume":"134","author":"U Wlotzke","year":"1996","unstructured":"Wlotzke, U., Hohenleutner, U., Abd-El-Raheem, T.A., Baumler, W. & Landthaler, M. Side-effects and complications of flashlamp-pumped pulsed dye laser therapy of port-wine stains. A prospective study. Br. J. Dermatol. 134, 475\u201380 (1996).","journal-title":"Br. J. Dermatol."},{"key":"BFsrep10344_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1046\/j.1472-8206.2003.00176.x","volume":"17","author":"DN Kiortsis","year":"2003","unstructured":"Kiortsis, D.N., Nikas, S., Hatzidimou, K., Tsianos, E. & Elisaf, M.S. Lipid-lowering drugs and serum liver enzymes: the effects of body weight and baseline enzyme levels. Fundam Clin. Pharmacol. 17, 491\u20134 (2003).","journal-title":"Fundam Clin. Pharmacol."},{"key":"BFsrep10344_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000063326","volume":"97","author":"A Muscari","year":"2002","unstructured":"Muscari, A., Puddu, G.M. & Puddu, P. Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology. 97, 115\u201321 (2002).","journal-title":"Cardiology"},{"key":"BFsrep10344_CR13","first-page":"439","volume":"13","author":"A Matkowski","year":"2013","unstructured":"Matkowski, A., Kus, P., Goralska, E. & Wozniak, D. Mangiferin - a bioactive xanthonoid, not only from mango and not just antioxidant. Mini Rev. Med. Chem. 13, 439\u201355 (2013).","journal-title":"Mini Rev. Med. Chem."},{"key":"BFsrep10344_CR14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.jnutbio.2012.09.003","volume":"24","author":"X Gong","year":"2013","unstructured":"Gong, X., et al. Anti-inflammatory effects of mangiferin on sepsis-induced lung injury in mice via up-regulation of heme oxygenase-1. J. Nutr. Biochem. 24, 1173\u201381 (2013).","journal-title":"J. Nutr. Biochem."},{"key":"BFsrep10344_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jep.2006.02.014","volume":"107","author":"S Prabhu","year":"2006","unstructured":"Prabhu, S., Jainu, M., Sabitha, K.E. & Devi, C.S. Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats. J. Ethnopharmacol. 107, 126\u201333 (2006).","journal-title":"J. Ethnopharmacol."},{"key":"BFsrep10344_CR16","first-page":"161","volume":"27","author":"PS Sellamuthu","year":"2014","unstructured":"Sellamuthu, P.S., Arulselvan, P., Fakurazi, S. & Kandasamy, M. Beneficial effects of mangiferin isolated from Salacia chinensis on biochemical and hematological parameters in rats with streptozotocin-induced diabetes. Pak J. Pharm. Sci. 27, 161\u20137 (2014).","journal-title":"Pak J. Pharm. Sci."},{"key":"BFsrep10344_CR17","doi-asserted-by":"crossref","unstructured":"Rodriguez, J., et al. Effects of a natural extract from Mangifera indica L and its active compound, mangiferin, on energy state and lipid peroxidation of red blood cells. Biochim. Biophys. Acta. 1760, 1333\u201342 (2006).","DOI":"10.1016\/j.bbagen.2006.04.005"},{"key":"BFsrep10344_CR18","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1248\/bpb.24.1091","volume":"24","author":"T Miura","year":"2001","unstructured":"Miura, T., et al. The suppressive effect of mangiferin with exercise on blood lipids in type 2 diabetes. Biol. Pharm. Bull. 24, 1091\u20132 (2001).","journal-title":"Biol. Pharm. Bull."},{"key":"BFsrep10344_CR19","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/mnfr.201100392","volume":"55","author":"F Guo","year":"2011","unstructured":"Guo, F., et al. Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters. Mol. Nutr. Food Res. 55, 1809\u201318 (2011).","journal-title":"Mol. Nutr. Food Res."},{"key":"BFsrep10344_CR20","doi-asserted-by":"publisher","first-page":"e30782","DOI":"10.1371\/journal.pone.0030782","volume":"7","author":"Y Niu","year":"2012","unstructured":"Niu, Y., et al. Mangiferin decreases plasma free fatty acids through promoting its catabolism in liver by activation of AMPK. PLoS One. 7, e30782 (2012).","journal-title":"PLoS One."},{"key":"BFsrep10344_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.foodchem.2011.10.079","volume":"132","author":"S Hou","year":"2012","unstructured":"Hou, S., et al. Pharmacokinetic study of mangiferin in human plasma after oral administration. Food Chem. 132, 289\u201394 (2012).","journal-title":"Food Chem."},{"key":"BFsrep10344_CR22","first-page":"1130","volume":"318","author":"TK Lam","year":"1988","unstructured":"Lam, T.K. & Leung, D.T. More on simplified calculation of body-surface area. N Engl. J. Med. 318, 1130 (1988).","journal-title":"N Engl. J. Med."},{"key":"BFsrep10344_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1194\/jlr.M200218-JLR200","volume":"44","author":"M Rodriguez","year":"2003","unstructured":"Rodriguez, M., et al. Plasma fatty acids and [13C]linoleic acid metabolism in preterm infants fed a formula with medium-chain triglycerides. J. Lipid Res. 44, 41\u20138 (2003).","journal-title":"J. Lipid Res."},{"key":"BFsrep10344_CR24","first-page":"839","volume":"19","author":"P Bjorntorp","year":"1995","unstructured":"Bjorntorp, P. Liver triglycerides and metabolism. Int. J. Obes. Relat. Metab. Disord. 19, 839\u201340 (1995).","journal-title":"Int. J. Obes. Relat. Metab. Disord"},{"key":"BFsrep10344_CR25","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1053\/meta.2001.25648","volume":"50","author":"JS Volek","year":"2001","unstructured":"Volek, J.S., et al. Effects of a high-fat diet on postabsorptive and postprandial testosterone responses to a fat-rich meal. Metabolism. 50, 1351\u20135 (2001).","journal-title":"Metabolism"},{"key":"BFsrep10344_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/mnfr.201000424","volume":"55","author":"R Ringseis","year":"2011","unstructured":"Ringseis, R. & Eder, K. Regulation of genes involved in lipid metabolism by dietary oxidized fat. Mol. Nutr. Food Res. 55, 109\u201321 (2011).","journal-title":"Mol. Nutr. Food Res."},{"key":"BFsrep10344_CR27","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.mcna.2011.06.003","volume":"95","author":"R Franssen","year":"2011","unstructured":"Franssen, R., Monajemi, H., Stroes, E.S. & Kastelein, J.J. Obesity and dyslipidemia. Med. Clin. North. Am. 95, 893\u2013902 (2011).","journal-title":"Med. Clin. North. Am."},{"key":"BFsrep10344_CR28","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1194\/jlr.M020404","volume":"53","author":"A Brautbar","year":"2012","unstructured":"Brautbar, A., et al. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J Lipid Res. 53, 556\u201360 (2012).","journal-title":"J Lipid Res."},{"key":"BFsrep10344_CR29","doi-asserted-by":"publisher","first-page":"e90137","DOI":"10.1371\/journal.pone.0090137","volume":"9","author":"J Lim","year":"2014","unstructured":"Lim, J., et al. Dual mode action of mangiferin in mouse liver under high fat diet. PLoS One. 9, e90137 (2014).","journal-title":"PLoS One."},{"key":"BFsrep10344_CR30","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.2337\/db14-0006","volume":"63","author":"P Apontes","year":"2014","unstructured":"Apontes, P., et al. Mangiferin stimulates carbohydrate oxidation and protects against metabolic disorders induced by high-fat diets. Diabetes. 63, 3626\u201336 (2014).","journal-title":"Diabetes"},{"key":"BFsrep10344_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/MOL.0b013e3283544956","volume":"23","author":"S Nielsen","year":"2012","unstructured":"Nielsen, S. & Karpe, F. Determinants of VLDL-triglycerides production. Curr. Opin. Lipidol. 23, 321\u20136 (2012).","journal-title":"Curr. Opin. Lipidol."},{"key":"BFsrep10344_CR32","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/nu5020498","volume":"5","author":"JO Ebbert","year":"2013","unstructured":"Ebbert, J.O. & Jensen, M.D. Fat depots, free fatty acids and dyslipidemia. Nutrients. 5, 498\u2013508 (2013).","journal-title":"Nutrients"},{"key":"BFsrep10344_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev.nutr.27.061406.093754","volume":"27","author":"SB Votruba","year":"2007","unstructured":"Votruba, S.B. & Jensen, M.D. Regional fat deposition as a factor in FFA metabolism. Annu. Rev. Nutr. 27, 149\u201363 (2007).","journal-title":"Annu. Rev. Nutr."},{"key":"BFsrep10344_CR34","doi-asserted-by":"publisher","first-page":"614","DOI":"10.2337\/diabetes.52.3.614","volume":"52","author":"B Teusink","year":"2003","unstructured":"Teusink, B., et al. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes. 52, 614\u201320 (2003).","journal-title":"Diabetes"},{"key":"BFsrep10344_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000350224","volume":"76","author":"FB Stephens","year":"2013","unstructured":"Stephens, F.B. & Galloway, S.D. Carnitine and fat oxidation. Nestle Nutr. Inst. Workshop Ser. 76, 13\u201323 (2013).","journal-title":"Nestle Nutr. Inst. Workshop Ser."},{"key":"BFsrep10344_CR36","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.metabol.2004.03.007","volume":"53","author":"KD Wutzke","year":"2004","unstructured":"Wutzke, K.D. & Lorenz, H. The effect of l-carnitine on fat oxidation, protein turnover and body composition in slightly overweight subjects. Metabolism. 53, 1002\u20136 (2004).","journal-title":"Metabolism"},{"key":"BFsrep10344_CR37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.metabol.2011.06.008","volume":"61","author":"MA Ramos-Roman","year":"2012","unstructured":"Ramos-Roman, M.A., Sweetman, L., Valdez, M.J. & Parks, E.J. Postprandial changes in plasma acylcarnitine concentrations as markers of fatty acid flux in overweight and obesity. Metabolism. 61, 202\u201312 (2012).","journal-title":"Metabolism"},{"key":"BFsrep10344_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10545-014-9704-9","volume":"37","author":"T Fukao","year":"2014","unstructured":"Fukao, T., et al. Ketone body metabolism and its defects. J. Inherit. Metab. Dis. 37, 541\u201351 (2014).","journal-title":"J. Inherit. Metab. Dis."},{"key":"BFsrep10344_CR39","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.nut.2008.09.006","volume":"25","author":"M Plourde","year":"2009","unstructured":"Plourde, M., Tremblay-Mercier, J., Fortier, M., Pifferi, F. & Cunnane, S.C. Eicosapentaenoic acid decreases postprandial beta-hydroxybutyrate and free fatty acid responses in healthy young and elderly. Nutrition. 25, 289\u201394 (2009).","journal-title":"Nutrition"},{"key":"BFsrep10344_CR40","first-page":"E694","volume":"254","author":"U Keller","year":"1988","unstructured":"Keller, U., Gerber, P.P. & Stauffacher, W. Fatty acid-independent inhibition of hepatic ketone body production by insulin in humans. Am. J. Physiol. 254, E694\u20139 (1988).","journal-title":"Am. J. Physiol."},{"key":"BFsrep10344_CR41","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/S0002-8223(02)90346-9","volume":"102","author":"P Trumbo","year":"2002","unstructured":"Trumbo, P., Schlicker, S., Yates, A.A. & Poos, M. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc. 102, 1621\u201330 (2002).","journal-title":"J Am Diet Assoc."},{"key":"BFsrep10344_CR42","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1016\/j.jchromb.2010.08.035","volume":"878","author":"L Liu","year":"2010","unstructured":"Liu, L., et al. Free fatty acid metabolic profile and biomarkers of isolated post-challenge diabetes and type 2 diabetes mellitus based on GC-MS and multivariate statistical analysis. J. Chromatogr B Analyt Technol. Biomed Life Sci. 878, 2817\u201325 (2010).","journal-title":"J. Chromatogr B Analyt Technol. Biomed Life Sci."},{"key":"BFsrep10344_CR43","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1053\/meta.2003.50102","volume":"52","author":"E Moro","year":"2003","unstructured":"Moro, E., et al. Hypertriglyceridemia is associated with increased insulin resistance in subjects with normal glucose tolerance: evaluation in a large cohort of subjects assessed with the 1999 World Health Organization criteria for the classification of diabetes. Metabolism. 52, 616\u20139 (2003 ).","journal-title":"Metabolism"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep10344","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep10344.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep10344.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T14:07:11Z","timestamp":1672927631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep10344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,19]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,9,22]]}},"alternative-id":["BFsrep10344"],"URL":"https:\/\/doi.org\/10.1038\/srep10344","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,19]]},"assertion":[{"value":"30 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10344"}}